英国BIA-ALCL诊疗指南:MHRA整形外科专家咨询组共识
该指南由英国MHRA整形、重建与美容外科专家咨询组制定,针对乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)提供循证系统框架。指南强调对任何有乳房植入物且出现新乳房症状者提高警惕以早期诊断,诊断基于植入物周围积液的细胞学、免疫组化和免疫表型评估(特征为ALK阴性、CD30强阳性),完整包膜全切除通常可治愈。
要点
- 任何乳房植入物者出现新乳房症状需警惕BIA-ALCL以早期诊断
- 诊断依据植入物周围积液细胞学及免疫组化:ALK阴性、CD30强阳性
- 完整包膜全切除(total en-bloc capsulectomy)通常可治愈
核心结论
- 采用结构化诊疗路径可实现BIA-ALCL早期诊断与成功治疗,减少系统治疗需求、降低并发症与不良结局风险。
研究设计与样本
- 由英国MHRA整形、重建与美容外科专家咨询组(PRASEAG)制定的循证指南,面向所有参与乳房植入物患者照护的临床医生。
主要发现
- BIA-ALCL是与乳房植入物相关的罕见T细胞非霍奇金淋巴瘤,肿瘤始于植入物包膜内面,可形成积液或较少见的包膜内组织肿块,可局部或远处播散。
- 诊断通常通过植入物周围积液的细胞学、免疫组化和免疫表型评估:多形性淋巴细胞特征性ALK阴性且CD30强阳性。
- BIA-ALCL多数患者呈惰性,但可快速进展;晚期诊断可能需要更根治性手术和系统治疗,虽有成功案例但也有不良结局和死亡报告。
关键数值与推荐
- 诊断依据植入物周围积液细胞学、免疫组化和免疫表型评估,特征为多形性淋巴细胞ALK阴性、CD30强阳性。
- 治疗以手术完整切除植入物及周围完整包膜(total en-bloc capsulectomy)通常可治愈。
临床怎么用
- 对任何有乳房植入物且出现新乳房症状者,应提高对BIA-ALCL可能性的认识以利早期诊断。
- 疑似或确诊BIA-ALCL患者应按指南结构化框架进行评估和治疗,优先考虑完整包膜全切除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T cell Non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK) negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimize the need for systemic treatments, reduce morbidity and the risk of poor outcomes. These guidelines provide an evidence-based and systematic framework for the assessment and treatment of patients with suspected or proven BIA-ALCL and are aimed at all clinicians involved in the care of people with breast implants.
引用
- Turton P, El-Sharkawi D, Lyburn I, et al. UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG). J Plast Reconstr Aesthet Surg. 2020. PMID: 33483089. doi:10.1016/j.bjps.2020.10.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。